Telix Pharmaceuticals

Telix Pharmaceuticals Inventory

The Inventory of Telix Pharmaceuticals (TLX.AX) as of Nov 19, 2026 is 37.08 M USD. In the previous year, Inventory was 23.62 M USD — a change of 56.99% (higher).

Inventory

37.08 MUSD

YoY

56.99%

Last updated:

Inventory of Telix Pharmaceuticals is 2025 37.08 M USD. Inventory of Telix Pharmaceuticals was 2024 23.62 M USD. It decreases by 56.99% higher compared to the previous year.

The Telix Pharmaceuticals Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
642,500.00 USD
Jan 1, 2019
542,000.00 USD
Jan 1, 2020
633,000.00 USD
Jan 1, 2021
3.45 M USD
Jan 1, 2022
5.50 M USD
Jan 1, 2023
12.74 M USD
Jan 1, 2024
23.62 M USD
Jan 1, 2025
37.08 M USD
The Telix Pharmaceuticals Inventory history
YEARInventoryYoY
37.08 MUSD+56.99%
23.62 MUSD+85.43%
12.74 MUSD+131.71%
5.50 MUSD+59.16%
3.45 MUSD+445.66%
633,000.00USD+16.79%
542,000.00USD-15.64%
642,500.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telix Pharmaceuticals stock

Inventory of Telix Pharmaceuticals is 37.08 M USD in 2025.

Inventory of Telix Pharmaceuticals changed from 23.62 M USD to 37.08 M USD, representing a 56.99% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Telix Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Telix Pharmaceuticals

All Key Metrics — Telix Pharmaceuticals